Loading…
Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates
We examined weight changes during chronic hepatitis C (CHC) therapy and association with virologic response. Weight changes were compared between subjects achieving rapid, early, and sustained virologic response rates (RVR, EVR, and SVR). RVR, EVR and SVR were compared among patients with or without...
Saved in:
| Published in: | International journal of medical sciences 2013-01, Vol.10 (13), p.1830-1836 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c375t-d58288a76d1e7db0bb25784c0bfbf603efd176a403ff1af097ae79bfda44859b3 |
|---|---|
| cites | |
| container_end_page | 1836 |
| container_issue | 13 |
| container_start_page | 1830 |
| container_title | International journal of medical sciences |
| container_volume | 10 |
| creator | Alwakeel, Hany R Zaghla, Hasan E Omar, Nabeel A Alashinnawy, Hasan A Rewisha, Eman A Matarese, Laura E Taha, Azza A Kandil, Hossam M |
| description | We examined weight changes during chronic hepatitis C (CHC) therapy and association with virologic response.
Weight changes were compared between subjects achieving rapid, early, and sustained virologic response rates (RVR, EVR, and SVR). RVR, EVR and SVR were compared among patients with or without weight loss of ≥ 0.5 body mass index (BMI) units (kg/m²) at 4, 12, 48 weeks.
CHC therapy was initiated in 184 cases. Median pretreatment BMI was 27.7 (18.4-51.3) with 38% overweight and 31% obese (BMI ≥25 and ≥ 30, respectively). Among patients with liver biopsies (n = 90), steatosis was present in 31.6%; fibrosis grade of 1-2/6 in 46%, 3-4 in 37.3% and 5-6 in 14.7%. Mean weight loss at 4, 12, 24 and 48 weeks of therapy were 1.2, 2.6, 3.8 and 3.3 kg, respectively. After 4 and 12 weeks of treatment, 38% and 54.3% had a BMI decrement of ≥ 0.5 kg/m². For genotype 1, weight loss at 4 weeks was associated with significantly higher EVR (90.0% vs. 70%, p = 0.01) and a tendency towards better RVR and SVR (42.9% vs. 26.0% and 55.2% vs. 34.8%, respectively, p = 0.08). In multivariate analysis, weight loss at 4 weeks was independently associated with EVR (OR 6.3, p = 0.02) but was not significantly associated with RVR or SVR.
Spontaneous weight loss at 4 and 12 weeks of CHC therapy was associated with improved EVR. Weight loss at 4 weeks was an independent predictor of EVR but not SVR. |
| doi_str_mv | 10.7150/ijms.6184 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3856373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24324359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-d58288a76d1e7db0bb25784c0bfbf603efd176a403ff1af097ae79bfda44859b3</originalsourceid><addsrcrecordid>eNpVUEtLAzEQDqLYWj34ByRXD1uTTXaz60GQ4gsKHtRzSHaT3ZRuUpK0xX9vSrVUGJgZvscMHwDXGE0ZLtCdWQxhWuKKnoAxprTOcI3Y6dE8AhchLBAiOWH4HIxySlIV9RiYj5WzUVjl1gFulen6CJte2E7Bdu2N7dLmnTUN7NVKRBNNgDMYvRJxUDbeQxGCa0xCnIVbE3u4Md4tXZcUXoVkHhT0IqpwCc60WAZ19dsn4Ov56XP2ms3fX95mj_OsIayIWVtUeVUJVrZYsVYiKfOCVbRBUktdIqJ0i1kpKCJaY6FRzYRitdStoLQqakkm4GHvu1rLQbVN-tKLJV95Mwj_zZ0w_D9iTc87t-GkKkrCSDK43Rs03oXglT5oMeK7vPkub77LO3Fvjo8dmH8Bkx--ioDT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates</title><source>NCBI_PubMed Central（免费）</source><creator>Alwakeel, Hany R ; Zaghla, Hasan E ; Omar, Nabeel A ; Alashinnawy, Hasan A ; Rewisha, Eman A ; Matarese, Laura E ; Taha, Azza A ; Kandil, Hossam M</creator><creatorcontrib>Alwakeel, Hany R ; Zaghla, Hasan E ; Omar, Nabeel A ; Alashinnawy, Hasan A ; Rewisha, Eman A ; Matarese, Laura E ; Taha, Azza A ; Kandil, Hossam M</creatorcontrib><description>We examined weight changes during chronic hepatitis C (CHC) therapy and association with virologic response.
Weight changes were compared between subjects achieving rapid, early, and sustained virologic response rates (RVR, EVR, and SVR). RVR, EVR and SVR were compared among patients with or without weight loss of ≥ 0.5 body mass index (BMI) units (kg/m²) at 4, 12, 48 weeks.
CHC therapy was initiated in 184 cases. Median pretreatment BMI was 27.7 (18.4-51.3) with 38% overweight and 31% obese (BMI ≥25 and ≥ 30, respectively). Among patients with liver biopsies (n = 90), steatosis was present in 31.6%; fibrosis grade of 1-2/6 in 46%, 3-4 in 37.3% and 5-6 in 14.7%. Mean weight loss at 4, 12, 24 and 48 weeks of therapy were 1.2, 2.6, 3.8 and 3.3 kg, respectively. After 4 and 12 weeks of treatment, 38% and 54.3% had a BMI decrement of ≥ 0.5 kg/m². For genotype 1, weight loss at 4 weeks was associated with significantly higher EVR (90.0% vs. 70%, p = 0.01) and a tendency towards better RVR and SVR (42.9% vs. 26.0% and 55.2% vs. 34.8%, respectively, p = 0.08). In multivariate analysis, weight loss at 4 weeks was independently associated with EVR (OR 6.3, p = 0.02) but was not significantly associated with RVR or SVR.
Spontaneous weight loss at 4 and 12 weeks of CHC therapy was associated with improved EVR. Weight loss at 4 weeks was an independent predictor of EVR but not SVR.</description><identifier>ISSN: 1449-1907</identifier><identifier>EISSN: 1449-1907</identifier><identifier>DOI: 10.7150/ijms.6184</identifier><identifier>PMID: 24324359</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject><![CDATA[Adult ; Aged ; Antiviral Agents - administration & dosage ; Antiviral Agents - therapeutic use ; Body Mass Index ; Female ; Hepacivirus - isolation & purification ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - physiopathology ; Hepatitis C, Chronic - virology ; Humans ; Interferon-alpha - administration & dosage ; Interferon-alpha - therapeutic use ; Male ; Middle Aged ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - therapeutic use ; Research Paper ; Retrospective Studies ; Ribavirin - administration & dosage ; Ribavirin - therapeutic use ; Viral Load ; Weight Loss ; Young Adult]]></subject><ispartof>International journal of medical sciences, 2013-01, Vol.10 (13), p.1830-1836</ispartof><rights>Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 2013</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-d58288a76d1e7db0bb25784c0bfbf603efd176a403ff1af097ae79bfda44859b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856373/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856373/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24324359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alwakeel, Hany R</creatorcontrib><creatorcontrib>Zaghla, Hasan E</creatorcontrib><creatorcontrib>Omar, Nabeel A</creatorcontrib><creatorcontrib>Alashinnawy, Hasan A</creatorcontrib><creatorcontrib>Rewisha, Eman A</creatorcontrib><creatorcontrib>Matarese, Laura E</creatorcontrib><creatorcontrib>Taha, Azza A</creatorcontrib><creatorcontrib>Kandil, Hossam M</creatorcontrib><title>Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates</title><title>International journal of medical sciences</title><addtitle>Int J Med Sci</addtitle><description>We examined weight changes during chronic hepatitis C (CHC) therapy and association with virologic response.
Weight changes were compared between subjects achieving rapid, early, and sustained virologic response rates (RVR, EVR, and SVR). RVR, EVR and SVR were compared among patients with or without weight loss of ≥ 0.5 body mass index (BMI) units (kg/m²) at 4, 12, 48 weeks.
CHC therapy was initiated in 184 cases. Median pretreatment BMI was 27.7 (18.4-51.3) with 38% overweight and 31% obese (BMI ≥25 and ≥ 30, respectively). Among patients with liver biopsies (n = 90), steatosis was present in 31.6%; fibrosis grade of 1-2/6 in 46%, 3-4 in 37.3% and 5-6 in 14.7%. Mean weight loss at 4, 12, 24 and 48 weeks of therapy were 1.2, 2.6, 3.8 and 3.3 kg, respectively. After 4 and 12 weeks of treatment, 38% and 54.3% had a BMI decrement of ≥ 0.5 kg/m². For genotype 1, weight loss at 4 weeks was associated with significantly higher EVR (90.0% vs. 70%, p = 0.01) and a tendency towards better RVR and SVR (42.9% vs. 26.0% and 55.2% vs. 34.8%, respectively, p = 0.08). In multivariate analysis, weight loss at 4 weeks was independently associated with EVR (OR 6.3, p = 0.02) but was not significantly associated with RVR or SVR.
Spontaneous weight loss at 4 and 12 weeks of CHC therapy was associated with improved EVR. Weight loss at 4 weeks was an independent predictor of EVR but not SVR.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Body Mass Index</subject><subject>Female</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - physiopathology</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Research Paper</subject><subject>Retrospective Studies</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - therapeutic use</subject><subject>Viral Load</subject><subject>Weight Loss</subject><subject>Young Adult</subject><issn>1449-1907</issn><issn>1449-1907</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVUEtLAzEQDqLYWj34ByRXD1uTTXaz60GQ4gsKHtRzSHaT3ZRuUpK0xX9vSrVUGJgZvscMHwDXGE0ZLtCdWQxhWuKKnoAxprTOcI3Y6dE8AhchLBAiOWH4HIxySlIV9RiYj5WzUVjl1gFulen6CJte2E7Bdu2N7dLmnTUN7NVKRBNNgDMYvRJxUDbeQxGCa0xCnIVbE3u4Md4tXZcUXoVkHhT0IqpwCc60WAZ19dsn4Ov56XP2ms3fX95mj_OsIayIWVtUeVUJVrZYsVYiKfOCVbRBUktdIqJ0i1kpKCJaY6FRzYRitdStoLQqakkm4GHvu1rLQbVN-tKLJV95Mwj_zZ0w_D9iTc87t-GkKkrCSDK43Rs03oXglT5oMeK7vPkub77LO3Fvjo8dmH8Bkx--ioDT</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Alwakeel, Hany R</creator><creator>Zaghla, Hasan E</creator><creator>Omar, Nabeel A</creator><creator>Alashinnawy, Hasan A</creator><creator>Rewisha, Eman A</creator><creator>Matarese, Laura E</creator><creator>Taha, Azza A</creator><creator>Kandil, Hossam M</creator><general>Ivyspring International Publisher</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20130101</creationdate><title>Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates</title><author>Alwakeel, Hany R ; Zaghla, Hasan E ; Omar, Nabeel A ; Alashinnawy, Hasan A ; Rewisha, Eman A ; Matarese, Laura E ; Taha, Azza A ; Kandil, Hossam M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-d58288a76d1e7db0bb25784c0bfbf603efd176a403ff1af097ae79bfda44859b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Body Mass Index</topic><topic>Female</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - physiopathology</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Research Paper</topic><topic>Retrospective Studies</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - therapeutic use</topic><topic>Viral Load</topic><topic>Weight Loss</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Alwakeel, Hany R</creatorcontrib><creatorcontrib>Zaghla, Hasan E</creatorcontrib><creatorcontrib>Omar, Nabeel A</creatorcontrib><creatorcontrib>Alashinnawy, Hasan A</creatorcontrib><creatorcontrib>Rewisha, Eman A</creatorcontrib><creatorcontrib>Matarese, Laura E</creatorcontrib><creatorcontrib>Taha, Azza A</creatorcontrib><creatorcontrib>Kandil, Hossam M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alwakeel, Hany R</au><au>Zaghla, Hasan E</au><au>Omar, Nabeel A</au><au>Alashinnawy, Hasan A</au><au>Rewisha, Eman A</au><au>Matarese, Laura E</au><au>Taha, Azza A</au><au>Kandil, Hossam M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates</atitle><jtitle>International journal of medical sciences</jtitle><addtitle>Int J Med Sci</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>10</volume><issue>13</issue><spage>1830</spage><epage>1836</epage><pages>1830-1836</pages><issn>1449-1907</issn><eissn>1449-1907</eissn><abstract>We examined weight changes during chronic hepatitis C (CHC) therapy and association with virologic response.
Weight changes were compared between subjects achieving rapid, early, and sustained virologic response rates (RVR, EVR, and SVR). RVR, EVR and SVR were compared among patients with or without weight loss of ≥ 0.5 body mass index (BMI) units (kg/m²) at 4, 12, 48 weeks.
CHC therapy was initiated in 184 cases. Median pretreatment BMI was 27.7 (18.4-51.3) with 38% overweight and 31% obese (BMI ≥25 and ≥ 30, respectively). Among patients with liver biopsies (n = 90), steatosis was present in 31.6%; fibrosis grade of 1-2/6 in 46%, 3-4 in 37.3% and 5-6 in 14.7%. Mean weight loss at 4, 12, 24 and 48 weeks of therapy were 1.2, 2.6, 3.8 and 3.3 kg, respectively. After 4 and 12 weeks of treatment, 38% and 54.3% had a BMI decrement of ≥ 0.5 kg/m². For genotype 1, weight loss at 4 weeks was associated with significantly higher EVR (90.0% vs. 70%, p = 0.01) and a tendency towards better RVR and SVR (42.9% vs. 26.0% and 55.2% vs. 34.8%, respectively, p = 0.08). In multivariate analysis, weight loss at 4 weeks was independently associated with EVR (OR 6.3, p = 0.02) but was not significantly associated with RVR or SVR.
Spontaneous weight loss at 4 and 12 weeks of CHC therapy was associated with improved EVR. Weight loss at 4 weeks was an independent predictor of EVR but not SVR.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>24324359</pmid><doi>10.7150/ijms.6184</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1449-1907 |
| ispartof | International journal of medical sciences, 2013-01, Vol.10 (13), p.1830-1836 |
| issn | 1449-1907 1449-1907 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3856373 |
| source | NCBI_PubMed Central（免费） |
| subjects | Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Body Mass Index Female Hepacivirus - isolation & purification Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - physiopathology Hepatitis C, Chronic - virology Humans Interferon-alpha - administration & dosage Interferon-alpha - therapeutic use Male Middle Aged Polyethylene Glycols - administration & dosage Polyethylene Glycols - therapeutic use Recombinant Proteins - administration & dosage Recombinant Proteins - therapeutic use Research Paper Retrospective Studies Ribavirin - administration & dosage Ribavirin - therapeutic use Viral Load Weight Loss Young Adult |
| title | Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A33%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spontaneous%20weight%20change%20during%20chronic%20hepatitis%20C%20treatment:%20association%20with%20virologic%20response%20rates&rft.jtitle=International%20journal%20of%20medical%20sciences&rft.au=Alwakeel,%20Hany%20R&rft.date=2013-01-01&rft.volume=10&rft.issue=13&rft.spage=1830&rft.epage=1836&rft.pages=1830-1836&rft.issn=1449-1907&rft.eissn=1449-1907&rft_id=info:doi/10.7150/ijms.6184&rft_dat=%3Cpubmed_cross%3E24324359%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-d58288a76d1e7db0bb25784c0bfbf603efd176a403ff1af097ae79bfda44859b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24324359&rfr_iscdi=true |